Select a medication above to begin.
Tivdak (tisotumab vedotin-tftv)
tisotumab vedotin
Black Box Warnings .
Ocular Toxicity
incl. changes in vision, severe vision loss and corneal ulceration can occur; withhold until improvement, then resume at reduced dose, or permanently D/C tx, based on severity; ophthalmic exam, incl. visual acuity, slit lamp exam, normal eye movement assessment, and ocular sx at baseline, before each cycle for cycles 1-9, and as clinically indicated; adhere to required premed and eye care before, during, and after infusion
Adult Dosing .
Dosage forms: INJ
Special Note
- [formulation clarification]
- Info: nonproprietary name = tisotumab vedotin-tftv
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, postmeds, and dosing incl. toxicity-related dose adjustments
cervical CA, recurrent or metastatic
- [2 mg/kg/dose IV q3wk]
- Max: 200 mg/dose; Info: see pkg insert for detailed eye care requirement before, during and after infusion
renal dosing
- [see below]
- CrCl >30: no adjustment; CrCl <30: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin >1.5x ULN or AST >3x ULN: avoid use
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.